



## SIMPONI ARIA (GOLIMUMAB) PATIENT REFERRAL AND PRESCRIPTION SHEET

Patient Information						
Patient Name:			Date:			
DOB:			Height:	☐ inches ☐ cm		
Allergies:			Weight:	□ lbs □ kg	☐ lbs ☐ kg	
Primary Diagnosis						
Diagnosis ICD-10 Diagnosis			ICD-10			
☐ Rheumatoid arthritis	M45	<del>                                     </del>	ritis with rheumatoid factor, unspecified		M05.9	
☐ Rheumatoid arthritis, unspecified	M06.9				M06.00	
☐ Juvenile rheumatoid polyarthritis (seronegative)	M08.3	☐ Other juvenile a	1	M08.80		
□ Psoriatic Arthritis	L40.52	Other:				
☐ Ankylosing Spondylitis	M45					
Medication Order						
Simponi Aria (Golimumab):  2 mg/kg IV at weeks 0,4 and then every 8 weeks x 1 year (initial dosing)  2 mg/kg IV every 8 weeks x 1 year  Other  Infusion will be administered over 30 minutes  Skilled nursing to assess and administer and/or teach self-administration where appropriate via access device as indicated below. Nursing will provide ongoing support as needed.				from dat signature indicated	☐ Refills x one year from date of signature unless indicated below	
Ancillary Orders						
□ Diphenhydramine: 25mg PO 30 min pre-infusion □ Acetaminophen: 650mg PO 30 min pre-infusion □ Famotidine: 20 mg PO x1 dose □ Other pre-meds: □ Refill x one year			Peripheral: NS 1-3 mL before/after use mplanted VAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw. Heparin (100 unit/mL) 3 to 5 mL final flush CVAD: NS 5 to 10 mL before/after use and 10 mL post-lab draw Heparin (10 units/mL) 3 to 5 mL final flush Refill x one year			
☐ Anaphylaxis Protocol: Epinephrine Auto-Injector dual pack: Adult: 0.3mg Children: 0.15 mg Administer epinephrine IM in the event of anaphylaxis. May repeat x 1 as needed, Call 911. Refill x 1yr						
Therapy Specific Documentation			Other Required Documentation			
Please include the following lab results required for infusion. If no results are available, the following labs will be drawn prior to first infusion:  Hepatitis B Surface Antigen Hepatitis B Core Antibody Total (not Core IgM) QuantiFERON TB Other:			<ul> <li>□ Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise.</li> <li>□ H&amp;P OR progress note(s)</li> <li>□ Medication List - please list past and present DMARDS and biologics below with dates of discontinue, if applicable</li> </ul>			
Provider Information						
Provider Name:			Provider Phone:			
Provider NPI:			Provider Fax:			
Provider Address:						
authorize Kaha Fusion and its representatives to act as an agent and initiate and execute any insurance arise such advantage or according to the control of						

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.

for the patient listed above. I understand that I can revoke this designation at any time by providing written notice to KabaFusion.

Prescriber Signature: \_\_\_

Date: \_\_\_\_\_